New Leqembi Data Revealed at CTAD 2025 Indicates Possible Delay in Disease Progression by Up to 8.3 Years with Ongoing Treatment

Lecanemab Treatment Findings: Recent data presented at the CTAD conference indicates that continued treatment with lecanemab (Leqembi®) can delay the progression of Alzheimer's disease by up to 8.3 years in patients with low amyloid levels who start treatment early.

Subcutaneous Formulation Approval: A new subcutaneous formulation of lecanemab, approved for maintenance treatment in the U.S. in August 2025, shows similar efficacy and safety to intravenous dosing, with a low incidence of systemic infusion reactions.

Long-term Benefits of Early Treatment: Analysis from clinical studies suggests that early initiation of lecanemab treatment can significantly slow disease progression, with time savings of up to 6.0 years from mild cognitive impairment to mild Alzheimer's and 8.3 years to moderate Alzheimer's in low-amyloid patients.

Collaboration and Commercialization: BioArctic and Eisai have a long-standing partnership for the development and commercialization of lecanemab, with BioArctic retaining rights for commercialization in the Nordic region while Eisai handles global regulatory and market approval processes.